On February 9, 2017, KEI filed written comments to the Office of the United States Trade Representative’s Special 301 Review process.
The Special 301 Review is an annual process carried out by the USTR to, “to identify countries that deny adequate and effective protection of intellectual property rights (IPR) or deny fair and equitable market access to U.S. persons who rely on intellectual property protection.”
In December 2016, during the twilight of President Barack Obama’s 44th presidency, the World Trade Organization (WTO) conducted a Trade Policy Review (TPR) of the United States of America. All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). The TPRM takes place in the “Trade Policy Review Body which is actually the WTO General Council — comprising the WTO’s full membership — operating under special rules and procedures” (Source: WTO, Trade Policy Reviews: Brief Introduction).
On the morning of Monday, 23 January 2017, India delivered the following intervention at the 140th session of the World Health Organization’s Executive Board requesting the “explicit inclusion” of the United Nations Secretary-General’s High-Level Panel Report in the “provisional agenda of the EB140 as a separate agenda item under item 8.”
In making the case for the inclusion of the UN HLP in the WHO’s Executive Board deliberations, India articulate the following:
At 11:06 P.M. on January 11, 2017, during the so-called “Vote-A-Rama”, the Senate considered an amendment put forward by Sen. Amy Klobuchar, D-Minn., and co-sponsored by Sen. Bernie Sanders, I-Vt., on the parallel importation of prescription drugs from Canada. Continue Reading
The Colombian Ministry of Health has finalized the price reduction of Glivec, Novartis’s +$47 billion leukemia drug, with a decrease in price from 368 pesos per milligram to 206.42 pesos per mg.
Matt Richtel and Andrew Pollack explore the complex policy issues involved with the pricing of products based on taxpayer-funded inventions and research in a front page New York Times story published today.
On Wednesday, 14 December 2016, the delegation of South Africa delivered a comprehensive, moving account of South Africa’s “journey in the quest to provide access to essential medicines” at WIPO’s Standing Committee on the Law of Patents.
South Africa Access to Medicines: South Africa’s Experience Related to the Topic of Access to Medicines at the Standing Committee on the Laws of PatentsBackground
Madam Vice Chair,
PCB39: Address of Justice Michael Kirby – HIV/AIDS & Solidarity – 30 Years On
On 7 December 2016, Justice Michael Kirby delivered the following keynote speech at the 39th Meeting of the UNAIDS Programme Coordinating Board during discussions on intellectual property and access to medicines. Justice Kirby served as a member of the United Nations Secretary-General’s High-Level Panel on Access to Medicines.
UNAIDS
PROGRAMME COORDINATING BOARD
39TH MEETING, WHO, GENEVA
AGENDA ITEM 6, 7 DECEMBER 2016HIV/AIDS & SOLIDARITY – 30 YEARS ON*
Michael Kirby**
SCP25: Statement of Asia Pacific Group on Patents and Health
On Tuesday, 13 December 2016, India delivered the following statement on behalf of the Asia and the Pacific Group during WIPO discussions on patents and health.
Statement by India on behalf of the Asia and the Pacific Group on the Agenda Item – Patents and Health – delivered by Dr. Sumit Seth, First Secretary (Economic Affairs) on 13 December 2016Madam Chair,
India has the honour to deliver this statement on behalf of the Asia Pacific Group. The group would like to make 3 concrete points related to this agenda item
SCP25: Statement of the Republic of South Africa on Patents and Health
On Tuesday, 13 December 2016, the Republic of South Africa delivered the following statement during the WIPO Standing Committee on the Law of Patents (SCP) discussions on patents and health.
WIPO Standing Committee on the Law of Patents (SCP) 13 December 2016Madam Chair
South Africa aligns itself with the statement delivered by Nigeria on behalf of the Africa Group.